Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
← catalyst calendarNCT07616206 · readout ≤ 254 d
Sponsored by vTv Therapeutics (industry) · VTVT — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes (T1D)
Interventions
- Drug: Cadisegliatin 800 mg QD — also filed as TTP399
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTo assess the change in Time in Range (TIR)
measured last 2 weeks of the two 6-week treatment periods
Permalink · VTVT's whole pipeline · Catalyst calendar · Every registered study · What changed